Researchers at the University of Arizona have discovered a way of preventing mosquito eggs from hatching, potentially paving the way for drugs that could serve as “birth control” within mosquito populations. Lead author Dr. Jun Isoe and colleagues hope the approach may provide a way of interrupting mosquito reproduction and reducing populations of the insects in areas of human disease transmission.
All news from R&D
Aptamer Group announced it has signed an agreement with AstraZeneca to explore the potential of using aptamer technology to target the kidney. The two-year agreement will give AstraZeneca use of Aptamer Group's proprietary technology to explore the feasibility of developing the next generation of drug delivery vehicles, called Aptamer Drug Conjugates (ApDCs).
Researchers publish the first data on the treatment of an age-related disease with drugs called senolytics. The results in patients with deadly idiopathic pulmonary fibrosis are encouraging and indicate the feasibility of larger clinical trials.
A naturally occurring protein called Tinagl1 reduced the spread of triple-negative breast cancer in a study conducted in mice. By simultaneously tackling two mechanisms for cancer's growth, an experimental therapy reduced the spread of triple-negative breast cancer in a study conducted in mice.
Mayo Clinic researchers and collaborators have shown that the obesity increases the level of "zombie" or senescent cells in the brain, and that those cells, in turn, are linked to anxiety. When senolytic drugs are used to clear those cells, the anxious behaviors in the mice dissipate. These findings appear in Cell Metabolism .
Researchers have launched a clinical trial to develop a breath test, analyzing molecules that could indicate the presence of cancer at an early stage. This is the first test of its kind to investigate multiple cancer types.
In an editorial published in CNS Spectrums , Jay Avasarala, MD, Ph.D., takes the research community to task for its lack of presentation in Phase III clinical trials for drugs to treat Multiple Sclerosis (MS).
Substituting trastuzumab emtansine (T-DM1, Kadcyla) for adjuvant trastuzumab (Herceptin) in patients who had residual disease after receiving neoadjuvant chemotherapy and trastuzumab reduced the risk of developing an invasive recurrence of HER2-positive early-stage breast cancer by 50%, according to data from the phase III clinical trial KATHERINE presented at the 2018 San Antonio Breast Cancer Symposium, held Dec. 4-8.
Incorporating genetic diversity into a mouse model of Alzheimer's disease resulted in greater overlap with the genetic, molecular and clinical features of this pervasive human disease, according to a new study.
Many clinical trials for breast cancer fail to give clear answers on the efficacy of new therapies, despite having thousands of patients and painstakingly tracking their outcomes for years. Now Yale Cancer Center (YCC) investigators have demonstrated that the most sophisticated models to assess patient risk for cancer can result in better clinical trials with more definitive results.
Women are underrepresented in clinical trials for heart failure, coronary artery disease and acute coronary syndrome but proportionately or overrepresented in trials for hypertension, atrial fibrillation and pulmonary arterial hypertension, when compared to incidence or prevalence of women within each disease population, according to a study in the Journal of the American College of Cardiology.
New research is first memory study to use intracranial recordings to better understand how maturation of the prefrontal cortex drives memory development.